Gene:
NFKB1
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  KBF1; NF-kB1; NF-kappaB; NFKB-p50; NFkappaB; p105; p50
PharmGKB Accession Id: PA248

Details

Cytogenetic Location: chr4 : q24 - q24
GP mRNA Boundary: chr4 : 103422486 - 103538459
GP Gene Boundary: chr4 : 103412486 - 103541459
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Doxorubicin Pathway (Cancer Cell), Pharmacodynamics
    Representation of the candidate genes involved in the action of doxorubicin in a stylized cancer cell.
  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.
  1. Tacrolimus/Cyclosporine Pathway, Pharmacodynamics
    Stylized cell depicting the mechanism of action of tacrolimus and cyclosporine, as well as the candidate genes believed to interact with the two drugs.

External Pathways

Links to non-PharmGKB pathways.

  1. Alternative NF-kappaB pathway - (Pathway Interaction Database NCI-Nature Curated)
  2. amb2 Integrin signaling - (Pathway Interaction Database NCI-Nature Curated)
  3. Angiopoietin receptor Tie2-mediated signaling - (Pathway Interaction Database NCI-Nature Curated)
  4. Atypical NF-kappaB pathway - (Pathway Interaction Database NCI-Nature Curated)
  5. BCR signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  6. Canonical NF-kappaB pathway - (Pathway Interaction Database NCI-Nature Curated)
  7. Ceramide signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  8. Downstream TCR signaling - (Reactome via Pathway Interaction Database)
  9. EPO signaling pathway - (Pathway Interaction Database NCI-Nature Curated)
  10. FAS signaling pathway (CD95) - (Pathway Interaction Database NCI-Nature Curated)
  11. HIV-1 Nef: Negative effector of Fas and TNF-alpha - (Pathway Interaction Database NCI-Nature Curated)
  12. IL1-mediated signaling events - (Pathway Interaction Database NCI-Nature Curated)
  13. IL12-mediated signaling events - (Pathway Interaction Database NCI-Nature Curated)
  14. IL2 signaling events mediated by PI3K - (Pathway Interaction Database NCI-Nature Curated)
  15. IL23-mediated signaling events - (Pathway Interaction Database NCI-Nature Curated)
  16. LPA receptor mediated events - (Pathway Interaction Database NCI-Nature Curated)
  17. NF-kB is activated and signals survival - (Reactome via Pathway Interaction Database)
  18. nf-kb signaling pathway - (BioCarta via Pathway Interaction Database)
  19. Osteopontin-mediated events - (Pathway Interaction Database NCI-Nature Curated)
  20. Regulated proteolysis of p75NTR - (Reactome via Pathway Interaction Database)
  21. Regulation of Telomerase - (Pathway Interaction Database NCI-Nature Curated)
  22. Signaling events mediated by HDAC Class I - (Pathway Interaction Database NCI-Nature Curated)
  23. TNF receptor signaling pathway - (Pathway Interaction Database NCI-Nature Curated)

Publications related to NFKB1: 14

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast cancer research : BCR. 2012. Liu Mohan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. International journal of cancer. Journal international du cancer. 2011. Nobili Stefania, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Network analysis of transcriptional regulation in response to intramuscular interferon-beta-1a multiple sclerosis treatment. The pharmacogenomics journal. 2010. Hecker M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. The pharmacogenomics journal. 2010. Ho-Pun-Cheung A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009. Barbie David A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009. Chang Ellen T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008. Hoskins Janelle M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genomic landscapes of human breast and colorectal cancers. Science (New York, N.Y.). 2007. Wood Laura D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphism discovery in 51 chemotherapy pathway genes. Human molecular genetics. 2005. Freimuth Robert R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2003. Roumestan C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. The Journal of clinical investigation. 2003. Tiede Imke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. The Biochemical journal. 2002. Wang Suwei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer cell. 2002. Yeoh Eng-Juh, et al. PubMed

LinkOuts

Entrez Gene:
4790
OMIM:
164011
UCSC Genome Browser:
NM_003998
RefSeq RNA:
NM_001165412
NM_003998
RefSeq Protein:
NP_001158884
NP_003989
RefSeq DNA:
AC_000047
AC_000136
NC_000004
NT_016354
NW_001838915
NW_922162
UniProtKB:
NFKB1_HUMAN (P19838)
Ensembl:
ENSG00000109320
GenAtlas:
NFKB1
GeneCard:
NFKB1
MutDB:
NFKB1
ALFRED:
LO030835T
HuGE:
NFKB1
Comparative Toxicogenomics Database:
4790
ModBase:
P19838
HumanCyc Gene:
HS03217
HGNC:
7794

Common Searches